ArticleScience (New York, N.Y.)2013
Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites.
Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 173 citations in OpenAlex.
- Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development.PLoS pathogens · 2026Article
- Article
- Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Review
- CRISPR/Cas genome editing, functional genomics, and diagnostics for parasitic helminths.International journal for parasitology · 2025Review
- Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-ResistantPharmaceutics · 2025Review
- Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Abundant genetic variation is retained in many laboratory schistosome populations.PLoS pathogens · 2025Article
- Pooled, Long-read Sequencing for Structural Variant Characterization in Schistosome Populations.Genome biology and evolution · 2025Article
- Detoxome Capacity of the Adult Rumen FlukeJournal of proteome research · 2025Article
- Chromosomal genome assembly resolves drug resistance loci in the parasitic nematode Teladorsagia circumcincta.PLoS pathogens · 2025Article
- Development and Application of an In Vitro Drug Screening Assay forBiomedicines · 2024Article
- Review
- Contribution of parasite and host genotype to immunopathology of schistosome infections.Parasites & vectors · 2024Article
- Trematode Genomics and Proteomics.Advances in experimental medicine and biology · 2024Article
- Computer-Aided Discovery ofBiomedical engineering and computational biology · 2024Article
- Identification of potent schistosomicidal compounds predicted as type II-kinase inhibitors againstFrontiers in parasitology · 2024Article
- Schistosomiasis.Advances in experimental medicine and biology · 2024Review
- Computer-Assisted Discovery ofBioinformatics and biology insights · 2024Article
- Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis.PLoS pathogens · 2023Article
- Using ChEMBL to Complement Schistosome Drug Discovery.Pharmaceutics · 2023Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
Abstract
Oxamniquine resistance evolved in the human blood fluke (Schistosoma mansoni) in Brazil in the 1970s. We crossed parental parasites differing ~500-fold in drug response, determined drug sensitivity and marker segregation in clonally derived second-generation progeny, and identified a single quantitative trait locus (logarithm of odds = 31) on chromosome 6. A sulfotransferase was identified as the causative gene by using RNA interference knockdown and biochemical complementation assays, and we subsequently demonstrated independent origins of loss-of-function mutations in field-derived and laboratory-selected resistant parasites. These results demonstrate the utility of linkage mapping in a human helminth parasite, while crystallographic analyses of protein-drug interactions illuminate the mode of drug action and provide a framework for rational design of oxamniquine derivatives that kill both S. mansoni and S. haematobium, the two species responsible for >99% of schistosomiasis cases worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.